Thermo Fisher Scientific (NYSE:TMO) CEO Marc N. Casper Sells 400 Shares

Key Points

• Thermo Fisher Scientific CEO Marc Casper sold 400 shares of the company's stock for a total of $200,200, decreasing his ownership by 0.35% while still retaining 113,762 shares.
• The company reported quarterly earnings of $5.36 per share, surpassing analyst expectations, with revenue of $10.86 billion, reflecting a 2.9% increase year-over-year.
• Thermo Fisher Scientific's recent quarterly dividend of $0.43 will be paid on October 15th, marking an annualized yield of 0.4% and a dividend payout ratio of 9.95%.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $11.93 during trading on Friday, hitting $479.48. 1,543,232 shares of the stock were exchanged, compared to its average volume of 1,555,589. The stock has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.62 and a beta of 0.75. The company has a fifty day moving average price of $466.86 and a 200-day moving average price of $451.08. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently bought and sold shares of TMO. Brighton Jones LLC boosted its holdings in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after purchasing an additional 461 shares during the period. Lionshead Wealth Management LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $446,000. Finally, LRI Investments LLC boosted its holdings in Thermo Fisher Scientific by 19.8% in the 4th quarter. LRI Investments LLC now owns 520 shares of the medical research company's stock valued at $270,000 after purchasing an additional 86 shares during the period. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on TMO. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $490.00 to $550.00 in a research note on Thursday. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Finally, Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.